A5000903509- Pulmonary Hypertension Research and Treatments
- Cardiovascular Function and Risk Factors
- Cardiovascular Issues in Pregnancy
- Vascular Anomalies and Treatments
- Liver Disease and Transplantation
- Transplantation: Methods and Outcomes
- Heart Failure Treatment and Management
- Venous Thromboembolism Diagnosis and Management
- Congenital Heart Disease Studies
- Hepatitis C virus research
- Cardiac Valve Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Metabolism and Genetic Disorders
- Cardiac tumors and thrombi
- Systemic Sclerosis and Related Diseases
- Sarcoma Diagnosis and Treatment
- Cardiomyopathy and Myosin Studies
- Dialysis and Renal Disease Management
- Myasthenia Gravis and Thymoma
- Dysphagia Assessment and Management
- Cancer Diagnosis and Treatment
- Phosphodiesterase function and regulation
- Neurological and metabolic disorders
- Restless Legs Syndrome Research
University of Bologna
2015-2024
Policlinico S.Orsola-Malpighi
2018-2024
Azienda USL di Bologna
2023-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
Istituto delle Scienze Neurologiche di Bologna
2024
Okayama Medical Center
2022
National Hospital Organization
2022
GNA University
2019
Pulmonary arterial hypertension is a severe disease with complex pathogenesis, for which combination therapy an attractive option.This study aimed to assess the impact of sequential on both short-term responses and long-term outcomes in real-world setting.Patients idiopathic/heritable pulmonary hypertension, or associated congenital heart connective tissue who were not meeting treatment goals either first-line bosentan sildenafil monotherapy, given additional assessed after 3-4 months....
Background Haemodynamic variables like right atrial pressure (RAP), cardiac index (CI), stroke volume (SVI) and mixed venous oxygen saturation ( S vO 2 ) predict survival in patients with pulmonary arterial hypertension (PAH). However, there is the need to identify further prognostic haemodynamic parameters as well redefine their role PAH risk stratification compared current tools non-invasive parameters. Methods This cohort study includes treatment-naïve assessed at baseline after...
Pulmonary arterial hypertension (PAH) is a severe clinical condition defined as mean pulmonary artery pressure ≥25 mmHg and normal capillary wedge (≤15 mmHg). In PAH the increase in due to an intrinsic disease of small arteries (resistance vessels) characterized by vascular proliferation remodeling. The resistance with subsequent elevation right ventricular afterload leads failure after variable periods time. Although targeted therapies have been developed over last decade that resulted...
The term pulmonary arterial hypertension (PAH) identifies a heterogeneous group of diseases characterized by progressive increase in resistance (PVR), which causes significant burden terms quality life, right heart failure and premature death. pathogenesis PAH is not completely clear: the remodeling small vessels crucial, causing an circle. Its diagnosis based on cardiac catheterization heart. According to present hemodynamic definition (PH) proposed Guidelines European Society...
To optimise treatment of patients with pulmonary arterial hypertension (PAH), the 2015 European Society Cardiology/European Respiratory guidelines recommend using risk stratification, aim achieving low-risk status. Previous analyses registries made progress in stratification approaches, however, focus is often on a prognosis, whereas most PAH are intermediate-risk or high-risk categories. Using only six parameters high prognostic relevance, we aimed to demonstrate pragmatic approach...
Background: Pulmonary endarterectomy (PEA) is the gold standard therapy for chronic thromboembolic pulmonary hypertension (CTEPH). Traditionally, vascular resistance (PVR) represents main prognostic factor after surgery. The artery pulsatility index (PAPi) has been proposed assessment of RV in advanced heart failure, but it never applied CTEPH patients. aim present study to describe PAPi patients who underwent PEA, before and surgery, define its predictive impact on postoperative outcomes....